ReviewNature clinical practice. Gastroenterology & hepatology2008
New concepts of resistance in the treatment of Helicobacter pylori infections.
Review in Nature clinical practice. Gastroenterology & hepatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 142 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple "Hybrid" and "Concomitant" Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance
Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)
Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial
Personalized Treatment for Refractory H Pylori Infection
Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication
The Efficacy of 10-day Metronidazole and Levofloxacin Containing Sequential Therapy and 10-day Levofloxacin-containing Triple Therapy In Second Line Helicobacter Pylori Eradication Therapies
Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication
Who cites it
142 citing papers in PubMed, 9 syntheses or guidelines pooled it, 353 citations in OpenAlex.
- Comparison of tegoprazan-based and proton pump inhibitor-based regimens forFrontiers in medicine · 2025Pooled it
- Tailored therapy forFrontiers in pharmacology · 2022Pooled it
- Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy forBioMed research international · 2019Pooled it
- Hybrid therapy for Helicobacter pylori infection: A systemic review and meta-analysis.World journal of gastroenterology · 2015Pooled it
- Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis.World journal of gastroenterology · 2015Pooled it
- Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?Journal of Korean medical science · 2014Pooled it
- Optimum duration of regimens for Helicobacter pylori eradication.The Cochrane database of systematic reviews · 2013Pooled it
- Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication.Helicobacter · 2009Pooled it
- Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis.British journal of cancer · 2009Pooled it
- Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days.Digestive diseases and sciences · 2024Trial
- Trial
- Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.Clinical and translational gastroenterology · 2020Trial
- Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.Frontiers of medicine · 2020Trial
- Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment forGut and liver · 2019Trial
- A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.Antimicrobial agents and chemotherapy · 2017Trial
- Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineCanadian journal of gastroenterology & hepatology · 2017Trial
- Trial
- Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial.Gut and liver · 2016Trial
- A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience.Medicine · 2016Trial
- Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance.World journal of gastroenterology · 2015Trial
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
The prevalence of antimicrobial drug resistance is now so high that all patients infected with Helicobacter pylori should be considered as having resistant infections. Ideally, therapy should be based on pretreatment antibiotic-susceptibility testing but this strategy is not currently practical. At present, clarithromycin-containing triple therapies do not reliably produce a > or =80% cure rate on an intention-to-treat basis and are, therefore, no longer acceptable as empiric therapy. In this Review, we discuss concepts of resistance that have become part of mainstream thinking for other infectious diseases but have not yet become so with regard to H. pylori. We also put data on the pharmacokinetics and pharmacodynamics of the drugs used in H. pylori therapy and the effect of host cytochrome P450 genotypes in context with treatment outcomes. Our primary focus is to address the problem of H. pylori resistance from a novel perspective, which also attempts to anticipate the direction that research will need to take to provide clinicians with reliable approaches to this serious infection. We also discuss current therapies that provide acceptable cure rates when used empirically (i.e. sequential therapy; four-drug, three-antibiotic, non-bismuth-containing 'concomitant' therapy; and bismuth-containing quadruple therapy) and how they might be further improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.